BR0304827A - Proteìna quimérica recombinante, e, cadeia de ácido nucléico - Google Patents

Proteìna quimérica recombinante, e, cadeia de ácido nucléico

Info

Publication number
BR0304827A
BR0304827A BR0304827-6A BR0304827A BR0304827A BR 0304827 A BR0304827 A BR 0304827A BR 0304827 A BR0304827 A BR 0304827A BR 0304827 A BR0304827 A BR 0304827A
Authority
BR
Brazil
Prior art keywords
ifn
nucleic acid
inhibits
chimeric protein
acid chain
Prior art date
Application number
BR0304827-6A
Other languages
English (en)
Inventor
Iraldo Bello Rivero
Yeny Torres Ruiz
Elizabeth Blanco Garces
Giselle Penton Roll
Pedro Lopez Saura
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of BR0304827A publication Critical patent/BR0304827A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

"PROTEìNA QUIMéRICA RECOMBINANTE, E, CADEIA DE áCIDO NUCLéICO". Proteína quimérica recombinante composta por um fragmento de 60 aminoácidos da região N-terminal da interleucina 2 (IL-2) humana fusionado à ponta N da região extracelular da cadeia alfa do receptor para IFN gama (IFN g). Esta proteina in vitro apresenta atividade estimuladora do crescimento de células T, inibe a atividade estimuladora do crescimento de IL-2 em células T, inibe a indução de HLA-DR pelo IFN g e inibe a atividade antiproliferativa do IFN g. Esta invenção pode ser aplicada no campo da medicina para o tratamento de várias patologias, como doenças auto-imunes, rejeição a transplantes, inflamações crónicas, sépse, síndrome de isquemia e reperfusão e aterosclerose.
BR0304827-6A 2002-05-10 2003-05-08 Proteìna quimérica recombinante, e, cadeia de ácido nucléico BR0304827A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20020095A CU23229A1 (es) 2002-05-10 2002-05-10 ANTAGONISTA QUIMéRICO ANTH1
PCT/CU2003/000006 WO2003095488A1 (es) 2002-05-10 2003-05-08 Antagonista quimérico anth1

Publications (1)

Publication Number Publication Date
BR0304827A true BR0304827A (pt) 2004-08-17

Family

ID=40091620

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0304827-6A BR0304827A (pt) 2002-05-10 2003-05-08 Proteìna quimérica recombinante, e, cadeia de ácido nucléico

Country Status (17)

Country Link
US (2) US7429384B2 (pt)
EP (1) EP1550672B1 (pt)
JP (1) JP4275065B2 (pt)
KR (1) KR20040108786A (pt)
CN (1) CN100384873C (pt)
AR (1) AR039973A1 (pt)
AT (1) ATE439379T1 (pt)
AU (1) AU2003223832B2 (pt)
BR (1) BR0304827A (pt)
CA (1) CA2485439A1 (pt)
CU (1) CU23229A1 (pt)
DE (1) DE60328807D1 (pt)
MX (1) MXPA04011143A (pt)
RU (1) RU2322455C2 (pt)
UA (1) UA81908C2 (pt)
WO (1) WO2003095488A1 (pt)
ZA (1) ZA200409073B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA023069B1 (ru) * 2008-04-09 2016-04-29 Корнелл Юниверсити Изолированные рекомбинантные кишечные симбиотические бактерии и их применение
BR112013008957A2 (pt) 2010-10-15 2019-09-24 Univ Cornell composições e métodos para tratamento de doenças endócrinas, gastrointestinais ou autoimunes
EP2994146B8 (en) * 2013-05-08 2021-05-19 Clene Nanomedicine, Inc. Methods and treatment for certain demyelination and dysmyelination-based disorders and/or promoting remyelination
CN107266586A (zh) * 2017-08-09 2017-10-20 安徽九川生物科技有限公司 一种重组猪长效干扰素γ及制备此长效干扰素γ的融合蛋白及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE132191T1 (de) * 1989-04-19 1996-01-15 Hoffmann La Roche Auflösbare interferon-gamma-rezeptoren sowie verfahren zu deren herstellung
US5073627A (en) * 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
CA2114168A1 (en) * 1993-03-05 1994-09-06 Zlatko Dembic Chimeric human interferon-gamma-receptor/immunoglobulin polypeptides
WO1994021282A1 (en) 1993-03-19 1994-09-29 Immunex Corporation Pharmaceutical compositions comprising a ligand complexed with a soluble receptor
US5582826A (en) * 1993-04-21 1996-12-10 Ajinomoto Co., Inc. Monoclonal antibodies which bind the gamma chain of human interleukin-2 receptor

Also Published As

Publication number Publication date
ATE439379T1 (de) 2009-08-15
AR039973A1 (es) 2005-03-09
EP1550672A1 (en) 2005-07-06
CU23229A1 (es) 2007-09-26
CA2485439A1 (en) 2003-11-20
US20070160575A1 (en) 2007-07-12
UA81908C2 (uk) 2008-02-25
CN100384873C (zh) 2008-04-30
KR20040108786A (ko) 2004-12-24
RU2004136170A (ru) 2005-05-27
WO2003095488A1 (es) 2003-11-20
JP2006506958A (ja) 2006-03-02
US7429384B2 (en) 2008-09-30
ZA200409073B (en) 2005-05-09
RU2322455C2 (ru) 2008-04-20
CN1662555A (zh) 2005-08-31
DE60328807D1 (de) 2009-09-24
AU2003223832A1 (en) 2003-11-11
MXPA04011143A (es) 2005-01-25
EP1550672B1 (en) 2009-08-12
US20060073115A1 (en) 2006-04-06
JP4275065B2 (ja) 2009-06-10
AU2003223832B2 (en) 2009-02-19

Similar Documents

Publication Publication Date Title
US10947288B2 (en) Targeting of human interferon antagonists
BRPI0513477A (pt) composições e processos de uso de proteìna 4 semelhante a angiotensina
PE20230849A1 (es) PROTEINAS DE FUSION INTERLEUCINA-2-Fc Y METODOS DE USO
CR7875A (es) Variantes de inmunoglobina y usos de esto
ATE544461T1 (de) Rekonstituierte tenside mit verbesserten eigenschaften
AR079701A1 (es) Proteinas solubles para su uso terapeutico
EA200501505A1 (ru) Антитела против il-22ra, их партнеры по связыванию и способы их применения при воспалениях
MX2021010809A (es) Citocina fusionada a fc heterodimerico, y composicion farmaceutica que comprende la misma.
WO2005059106A3 (en) Interferon alpha antibodies and their uses
HUP0400466A2 (hu) G-CSF konjugátumok
DE68929043T2 (de) Für androgen-rezeptor-protein kodierende dna
ES2149167T3 (es) Factor transformante del crecimiento tipo beta.
AR115083A1 (es) Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1
MXPA05008704A (es) Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas.
CU23149A3 (es) PROCESO PARA LA PURIFICACION DE PROTEINAS FARMACOLOGICAMENTE ACTIVAS A TRAVéS DE CROMATOGRAFIA DE INTERCAMBIO CATIONICO
IS2819B (is) Viðloðunarsameindir í æðum og mótun á starfsemi@þeirra
BR0304827A (pt) Proteìna quimérica recombinante, e, cadeia de ácido nucléico
DE60106002D1 (de) Behandlung von hematopoietischen zellen mit cxcr4 agonisten
DK2229440T3 (da) Rekombinante elastase-proteiner og fremgangsmåder til fremstilling og anvendelse deraf
DK0932689T3 (da) Assay for homocystein og homocysteindesulphurase fra protozo-trichomonas vaginalis
EA202092458A1 (ru) Композиции на основе рекомбинантного слитого белка, содержащего нейрегулин-1 (nrg-1) человека, и способы их применения
BR112022005426A2 (pt) Polipeptídeos de fusão dap10/dap12
ES2192199T3 (es) Ligandos de la familia eph biologicamente activos.
Steinbach et al. Recombinant equine interferons: expression cloning and biological activity
DE602005011321D1 (de) Deamidiertes interferon-beta

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A(S) 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2112 DE 28/06/2011.